A Study of Ivonescimab in People With Endometrial and Cervical Cancers

Conditions

• Cervical Cancer
• Endometrial Cancer

Eligibility Criteria

Sex

FEMALE

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Ivonescimab — DRUG
  Ivonescimab will be administered as 20 mg/kg IV (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥ 160 kg), Q3W administered for 60 minutes (± 10 minutes)

Study Details

The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.

Key Dates

Start date

Apr 4, 2025

Status verified

Mar 2026

Primary completion

Apr 30, 2027

Completion

Apr 4, 2027

Study Design

Enrollment

50 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Ivonescimab in People With Endometrial Cancer
  Study treatment will be given sequentially on the first day of each cycle in a 3-week dosing cycle: Ivonescimab will be administered as 20 mg/kg IV (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥ 160 kg), Q3W administered for 60 minutes (± 10 minutes). The total duration of ivonescimab treatment is up to 24 months.
• Experimental: Ivonescimab in People With Cervical Cancer
  Study treatment will be given sequentially on the first day of each cycle in a 3-week dosing cycle: Ivonescimab will be administered as 20 mg/kg IV (a fixed dose of 3200 mg for ivonescimab should be used for patients ≥ 160 kg), Q3W administered for 60 minutes (± 10 minutes). The total duration of ivonescimab treatment is up to 24 months.

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: 27 weeks ]

Central Contacts

• Maria Rubinstein, MD
  646-888-6954
  [email protected]
• Vicky Makker, MD
  646-888-4224
  [email protected]

Locations (7)

Find similar trials in Basking Ridge, NJ

Related Studies

• Integrated Cancer Repository for Cancer Research
  Recruiting · University of Nebraska · Greenwood Village, Colorado
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  Recruiting · Massive Bio, Inc. · Birmingham, Alabama
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
  PHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Birmingham, Alabama
• Vaginal Cuff Brachytherapy Fractionation Study
  PHASE3 · Recruiting · Kara Romano, MD · Baltimore, Maryland